1. Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Manry J, et al. (175名中37番目)Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol. 2021 Aug 19;6(62):eabl4340. doi: 10.1126/sciimmunol.abl4340..
2. Kuehn HS, Chang J, Yamashita M, Niemela JE, Zou C, Okuyama K, et al. (18名中15番目) T and B cell abnormalities, pneumocystis pneumonia, and chronic lymphocytic leukemia associated with an AIOLOS defect in patients. J Exp Med. 2021 Dec 6;218(12):e20211118. doi: 10.1084/jem.20211118. Epub 2021 Oct 25.
3. Yamashita M, Kuehn HS, Okuyama K, Okada S, Inoue Y, Mitsuiki N, Imai K, Takagi M, Kanegane H, Takeuchi M, Shimojo N, Tsumura M, Padhi AK, Zhang KYJ, Boisson B, Casanova JL, Ohara O, Rosenzweig SD, Taniuchi I, Morio T. A variant in human AIOLOS impairs adaptive immunity by interfering with IKAROS. Nat Immunol. 2021 Jul;22(7):893-903. doi: 10.1038/s41590-021-00951-z. Epub 2021 Jun 21.
4. Magg T, Okano T, Koenig LM, Boehmer DFR, Schwartz SL, Inoue K, Heimall J, Licciardi F, Ley-Zaporozhan J, Ferdman RM, Caballero-Oteyza A, Park EN, Calderon BM, Dey D, Kanegane H, Cho K, Montin D, Reiter K, Griese M, Albert MH, Rohlfs M, Gray P, Walz C, Conn GL, Sullivan KE, Klein C, Morio T (corresponding), Hauck F. Heterozygous OAS1 gain-of-function variants cause an autoinflammatory immunodeficiency. Sci Immunol. 2021 Jun 18;6(60):eabf9564. doi: 10.1126/sciimmunol.abf9564.
5. Kamiya T, Morio T. Viral infections after hematopoietic cell transplantation and treatment with virus-specific T-cell therapies. Rinsho Ketsueki. 2021;62(8):1334-1342. doi: 10.11406/rinketsu.62.1334.
6. Nakasone H, Kako S, Tachibana T, Tanaka M, Onizuka M, Takahashi S, Yokota A, Fujiwara SI, Sakura T, Sakaida E, Fujisawa S, Yamazaki R, Gotoh M, Hagihara M, Aotsuka N, Tsukada N, Hatta Y, Shimizu H, Usuki K, Watanabe R, Mori T, Yano S, Kanamori H, Kanda Y. Novel indicators of transplant outcomes for PhALL: current molecular-relapse-free survival". Transplant Cell Ther. 2021 Sep;27(9):800.e1-800.e8. doi: 10.1016/j.jtct.2021.06.020. Epub 2021 Jun 24."
7. Shimomura Y, Hara M, Konuma T, Itonaga H, Doki N, Ozawa Y, Eto T, Uchida N, Aoki J, Kato J, Onishi Y, Takahashi S, Fukushima K, Nakamae H, Kawakita T, Tanaka J, Fukuda T, Atsuta Y, Ishikawa T, Ishiyama K. Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome in adolescent and young adult patients. Bone Marrow Transplant. 2021 Oct;56(10):2510-2517. doi: 10.1038/s41409-021-01324-8. Epub 2021 May 15
8. Konuma T, Monna-Oiwa M, Isobe M, Okabe M, Takahashi S, Tojo A. Radiation-free myeloablative conditioning consisting of fludarabine added to full-dose busulfan and cyclophosphamide in single-unit cord blood transplantation for adults. Eur J Haematol. 2021 Sep;107(3):374-376. doi: 10.1111/ejh.13669. Epub 2021 May 30.
9. Kaito Y, Konuma T, Monna-Oiwa M, Kato S, Isobe M, Okabe M, Imai Y, Takahashi S, Tojo A. Prognostic impacts of peripheral blood erythroblasts after single-unit cord blood transplantation. Int J Lab Hematol. 2021 Dec;43(6):1437-1442. doi: 10.1111/ijlh.13622. Epub 2021 Jun 12
10. Takahashi H, Okayama N, Yamaguchi N, Nomura M, Miyahara Y, Mahbub MH, Hase R, Morishima Y, Suehiro Y, Yamasaki T, Tamada K, Takahashi S, Tojo A, Tanabe T. Analysis of Relationships between Immune Checkpoint and Methylase Gene Polymorphisms and Outcomes after Unrelated Bone Marrow Transplantation. Cancers (Basel). 2021 Jun 1;13(11):2752. doi: 10.3390/cancers13112752. PMID: 3420608